摘要
目的评价β-受体阻滞剂美托洛尔联合依那普利治疗慢性充血性心力衰竭(CHF)的疗效和安全性。方法选择我院CHF患者90例,随机分为对照组45例,常规给予依那普利,利尿剂,部分患者用洋地黄。治疗组45例,在此基础上加用美托洛尔,观察治疗前、后两组患者的疗效及对心率、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)的影响及其安全性。结果两组患者疗效间差异有非常显著性意义(P<0·01)。两组患者治疗前、后心率、LVEF间差异均有显著性意义(P<0·05)。结论CHF患者长期应用美托洛尔能改善心功能,LVEDD治疗前、后无改善可能与观察例数较少有关,有待于增加例数,进一步研究。
Objective To assess the safety and efficacy of using Beta - adrenergic receptor blockade betaloc and enalapril in treating chronic heart failure （CHF）. Methods Ninty patients with CHF were randomly allocated into two groups, one group treated with ACEI （enalapril）, diuretic digitalis （45cases） and other group added betaloc on the base, the treatment resuits were compared between two groups. Results In betaloc group, the heart rate were slower, the left ventricuiar ejection fraction were higher, left ventricular end diastolic diameter were significantly lower than control group （ P 〈 0. 05）. Conclusion Betaloc and enalapril show safty and efficacy in treating CHF. Reduce the in - hospital mortality rate and the rate of rehospitalization.
出处
《实用心脑肺血管病杂志》
2006年第11期883-884,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
